Market Cap 11.97M
Revenue (ttm) 41.71M
Net Income (ttm) -10.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -25.27%
Debt to Equity Ratio 0.78
Volume 42,587
Avg Vol 186,174
Day's Range N/A - N/A
Shares Out 12.80M
Stochastic %K 56%
Beta 0.83
Analysts Sell
Price Target $6.00

Company Profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 781 245 1325
Address:
660 Main Street, 1st Floor, Woburn, United States
Kings124566
Kings124566 Jun. 5 at 10:00 PM
$BFRI Jfin and Lx are already profitable, pay a dividend, and well below book value and super low P/E ratios.
0 · Reply
Tonyboner
Tonyboner Jun. 5 at 7:06 PM
$BFRI Total market crash
0 · Reply
FreeRunner
FreeRunner Jun. 5 at 6:05 PM
$BFRI Legitimate question : How a company with $10M revenue for Q1 can be valued at $12M? What am I missing?
0 · Reply
ivo98
ivo98 Jun. 5 at 2:11 PM
$BFRI FDA Decision on 28 September is not for a new product, it's for use Ameluz. Bfri sales only 1 product and lamps. Be aware of pumping new members with there "28 September". 12 mlj outstanding and increasing. 🤔🤫
0 · Reply
jcooptechit
jcooptechit Jun. 4 at 5:44 PM
$MDCX MULTI-BILLION DOLLAR SKIN CANCER MARKET OPPORUNITY 🧬 Medicus Pharma advanced SkinJect into registrational development for Gorlin Syndrome which is a rare disease where patients can face hundreds of basal cell carcinomas over a lifetime. 🔹 FDA Phase 2b protocol submitted 🔹 Potential first lesion-directed therapy 🔹 Orphan Drug + Rare Pediatric Disease Voucher strategy 🔹 Encouraging Phase 2 clearance + safety data SkinJect could help reduce repeated surgeries while targeting a massive BCC / non-melanoma skin cancer market. 📌 Add MDCX to your watchlist. Communicated - Disclaimer: https://stockresearchtoday.com/mdcx/ Sector Peers: $BFRI $REPL $IDYA $MDWD
2 · Reply
race2zero
race2zero Jun. 4 at 12:53 PM
$BFRI $CLDI $DOGZ $GRRR deep value for $CLDI? Yes, please join us in shorting it . Reverse split vote ends next Thursday (perfect for a Friday PR). 1-16 split with 9+ million dilution built in. Will be the easiest short ever
0 · Reply
tiddyy
tiddyy Jun. 3 at 3:19 PM
$BBAI Took some change out but I am back again after making some money on $BFRI
1 · Reply
ivo98
ivo98 Jun. 3 at 2:01 PM
$BFRI @Tonyboner if you have Q1 10.08 mlj revenues and 14.4 mlj total operating expenses we are talking about a cash-burning company. They did not touch their cash but used other assets. These are not finite, and they will quickly use up their cash and need new ones (offering). They have only 1 drug approved and selling --> Ameluz. Most trials are with Ameluz and for a different working area and with/or a RhodoLED lamp.
1 · Reply
ivo98
ivo98 Jun. 3 at 6:33 AM
$BFRI >12 mlj outstanding shares and not enough cash to survive 2026 without making a new offering. 1 product "Ameluz" sales.
1 · Reply
Tonyboner
Tonyboner Jun. 2 at 6:01 PM
$BFRI Looks like int are buying slowly, good moves in the last few weeks, think this blows soon, like to see $1.50S on this one. they have cash and very low float, with a few million shares we will see some big moves, they have a lot of drugs approved.
0 · Reply
Latest News on BFRI
Biofrontera Earnings Call Transcript: Q1 2026

May 14, 2026, 11:00 AM EDT - 25 days ago

Biofrontera Earnings Call Transcript: Q1 2026


Biofrontera Earnings release: Q1 2026

May 14, 2026, 11:00 AM EDT - 25 days ago

Biofrontera Earnings release: Q1 2026


Biofrontera Quarterly report: Q1 2026

May 14, 2026, 11:00 AM EDT - 25 days ago

Biofrontera Quarterly report: Q1 2026


Biofrontera Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Biofrontera Proxy statement: Proxy filing


Biofrontera Earnings Call Transcript: Q4 2025

Mar 19, 2026, 10:00 AM EDT - 2 months ago

Biofrontera Earnings Call Transcript: Q4 2025


Biofrontera Annual report: Q4 2025

Mar 19, 2026, 10:00 AM EDT - 2 months ago

Biofrontera Annual report: Q4 2025


Biofrontera Earnings release: Q4 2025

Mar 19, 2026, 10:00 AM EDT - 2 months ago

Biofrontera Earnings release: Q4 2025


Biofrontera reports Q4 revenue $17.1M vs. $12.6M last year

2026-03-19T13:36:56.000Z - 2 months ago

Biofrontera reports Q4 revenue $17.1M vs. $12.6M last year


Biofrontera announces FDA acceptance of sNDA for Ameluz PDT

2026-02-11T14:20:35.000Z - 4 months ago

Biofrontera announces FDA acceptance of sNDA for Ameluz PDT


Biofrontera announces positive Phase 3 results for Ameluz PDT

2026-02-09T14:25:30.000Z - 4 months ago

Biofrontera announces positive Phase 3 results for Ameluz PDT


Biofrontera reports preliminary Q4 revenue $17M-$17.5M

2026-01-13T13:36:29.000Z - 5 months ago

Biofrontera reports preliminary Q4 revenue $17M-$17.5M


Biofrontera announces data base locks for two clinical studies

2026-01-08T14:01:20.000Z - 5 months ago

Biofrontera announces data base locks for two clinical studies


Biofrontera completes transfer of Ameluz, RhodoLED FDA approval

2025-12-18T13:51:20.000Z - 6 months ago

Biofrontera completes transfer of Ameluz, RhodoLED FDA approval


Biofrontera Registration statement: Registration Filing

Dec 5, 2025, 7:00 AM EST - 6 months ago

Biofrontera Registration statement: Registration Filing


Biofrontera files sNDA for Ameluz-PDT in treatment of sBCC

2025-12-02T13:50:16.000Z - 6 months ago

Biofrontera files sNDA for Ameluz-PDT in treatment of sBCC


Biofrontera Earnings Call Transcript: Q3 2025

Nov 13, 2025, 10:00 AM EST - 7 months ago

Biofrontera Earnings Call Transcript: Q3 2025


Biofrontera Earnings release: Q3 2025

Nov 13, 2025, 10:00 AM EST - 7 months ago

Biofrontera Earnings release: Q3 2025


Biofrontera Quarterly report: Q3 2025

Nov 13, 2025, 10:00 AM EST - 7 months ago

Biofrontera Quarterly report: Q3 2025


Biofrontera reports Q3 EPS (62c) vs (98c) last year

2025-11-13T13:21:24.000Z - 7 months ago

Biofrontera reports Q3 EPS (62c) vs (98c) last year


Biofrontera Earnings Call Transcript: Q2 2025

Aug 14, 2025, 10:00 AM EDT - 10 months ago

Biofrontera Earnings Call Transcript: Q2 2025


Biofrontera Earnings release: Q2 2025

Aug 14, 2025, 10:00 AM EDT - 10 months ago

Biofrontera Earnings release: Q2 2025


Biofrontera Quarterly report: Q2 2025

Aug 14, 2025, 10:00 AM EDT - 10 months ago

Biofrontera Quarterly report: Q2 2025


Biofrontera Registration statement: Registration Filing

Aug 13, 2025, 8:00 AM EDT - 10 months ago

Biofrontera Registration statement: Registration Filing


Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

Aug 11, 2025, 4:25 PM EDT - 10 months ago

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer


Biofrontera Proxy statement: Proxy Filing

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Biofrontera Proxy statement: Proxy Filing


Biofrontera Proxy statement: Proxy Filing

Jul 25, 2025, 8:00 AM EDT - 11 months ago

Biofrontera Proxy statement: Proxy Filing


Biofrontera Registration statement: Registration Filing

Jul 16, 2025, 8:00 AM EDT - 11 months ago

Biofrontera Registration statement: Registration Filing


Biofrontera Proxy statement: Proxy Filing

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Biofrontera Proxy statement: Proxy Filing


Biofrontera Earnings Call Transcript: Q1 2025

May 16, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Earnings Call Transcript: Q1 2025


Biofrontera Earnings release: Q1 2025

May 16, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Earnings release: Q1 2025


Biofrontera Quarterly report: Q1 2025

May 16, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Quarterly report: Q1 2025


Biofrontera Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Biofrontera Proxy statement: Proxy Filing


Biofrontera Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Biofrontera Proxy statement: Proxy Filing


Biofrontera Earnings Call Transcript: Q4 2024

Mar 21, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Earnings Call Transcript: Q4 2024


Biofrontera Earnings release: Q4 2024

Mar 21, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Earnings release: Q4 2024


Biofrontera Annual report: Q4 2024

Mar 21, 2025, 10:00 AM EDT - 1 year ago

Biofrontera Annual report: Q4 2024


Biofrontera Registration statement: Registration Filing

Jan 17, 2025, 7:00 AM EST - 1 year ago

Biofrontera Registration statement: Registration Filing


Biofrontera Earnings Call Transcript: Q3 2024

Nov 14, 2024, 10:00 AM EST - 1 year ago

Biofrontera Earnings Call Transcript: Q3 2024


Biofrontera Quarterly report: Q3 2024

Nov 14, 2024, 10:00 AM EST - 1 year ago

Biofrontera Quarterly report: Q3 2024


Biofrontera Earnings release: Q3 2024

Nov 14, 2024, 10:00 AM EST - 1 year ago

Biofrontera Earnings release: Q3 2024


Biofrontera Earnings Call Transcript: Q2 2024

Aug 15, 2024, 10:00 AM EDT - 1 year ago

Biofrontera Earnings Call Transcript: Q2 2024


Biofrontera Quarterly report: Q2 2024

Aug 15, 2024, 10:00 AM EDT - 1 year ago

Biofrontera Quarterly report: Q2 2024


Biofrontera Earnings release: Q2 2024

Aug 15, 2024, 10:00 AM EDT - 1 year ago

Biofrontera Earnings release: Q2 2024


Biofrontera Earnings Call Transcript: Q1 2024

May 16, 2024, 10:00 AM EDT - 2 years ago

Biofrontera Earnings Call Transcript: Q1 2024


Biofrontera Quarterly report: Q1 2024

May 16, 2024, 10:00 AM EDT - 2 years ago

Biofrontera Quarterly report: Q1 2024


Biofrontera Earnings release: Q1 2024

May 16, 2024, 10:00 AM EDT - 2 years ago

Biofrontera Earnings release: Q1 2024


Kings124566
Kings124566 Jun. 5 at 10:00 PM
$BFRI Jfin and Lx are already profitable, pay a dividend, and well below book value and super low P/E ratios.
0 · Reply
Tonyboner
Tonyboner Jun. 5 at 7:06 PM
$BFRI Total market crash
0 · Reply
FreeRunner
FreeRunner Jun. 5 at 6:05 PM
$BFRI Legitimate question : How a company with $10M revenue for Q1 can be valued at $12M? What am I missing?
0 · Reply
ivo98
ivo98 Jun. 5 at 2:11 PM
$BFRI FDA Decision on 28 September is not for a new product, it's for use Ameluz. Bfri sales only 1 product and lamps. Be aware of pumping new members with there "28 September". 12 mlj outstanding and increasing. 🤔🤫
0 · Reply
jcooptechit
jcooptechit Jun. 4 at 5:44 PM
$MDCX MULTI-BILLION DOLLAR SKIN CANCER MARKET OPPORUNITY 🧬 Medicus Pharma advanced SkinJect into registrational development for Gorlin Syndrome which is a rare disease where patients can face hundreds of basal cell carcinomas over a lifetime. 🔹 FDA Phase 2b protocol submitted 🔹 Potential first lesion-directed therapy 🔹 Orphan Drug + Rare Pediatric Disease Voucher strategy 🔹 Encouraging Phase 2 clearance + safety data SkinJect could help reduce repeated surgeries while targeting a massive BCC / non-melanoma skin cancer market. 📌 Add MDCX to your watchlist. Communicated - Disclaimer: https://stockresearchtoday.com/mdcx/ Sector Peers: $BFRI $REPL $IDYA $MDWD
2 · Reply
race2zero
race2zero Jun. 4 at 12:53 PM
$BFRI $CLDI $DOGZ $GRRR deep value for $CLDI? Yes, please join us in shorting it . Reverse split vote ends next Thursday (perfect for a Friday PR). 1-16 split with 9+ million dilution built in. Will be the easiest short ever
0 · Reply
tiddyy
tiddyy Jun. 3 at 3:19 PM
$BBAI Took some change out but I am back again after making some money on $BFRI
1 · Reply
ivo98
ivo98 Jun. 3 at 2:01 PM
$BFRI @Tonyboner if you have Q1 10.08 mlj revenues and 14.4 mlj total operating expenses we are talking about a cash-burning company. They did not touch their cash but used other assets. These are not finite, and they will quickly use up their cash and need new ones (offering). They have only 1 drug approved and selling --> Ameluz. Most trials are with Ameluz and for a different working area and with/or a RhodoLED lamp.
1 · Reply
ivo98
ivo98 Jun. 3 at 6:33 AM
$BFRI >12 mlj outstanding shares and not enough cash to survive 2026 without making a new offering. 1 product "Ameluz" sales.
1 · Reply
Tonyboner
Tonyboner Jun. 2 at 6:01 PM
$BFRI Looks like int are buying slowly, good moves in the last few weeks, think this blows soon, like to see $1.50S on this one. they have cash and very low float, with a few million shares we will see some big moves, they have a lot of drugs approved.
0 · Reply
LongBullish
LongBullish Jun. 2 at 4:44 PM
$BFRI Transformed its business by acquiring full U.S. commercial rights for its flagship photodynamic therapy drug, Ameluz. The FDA set a critical PDUFA action date of September 28, 2026, to review Ameluz for superficial basal cell carcinoma. What's taking $NWBO so long with DCVax-L?
1 · Reply
Tonyboner
Tonyboner Jun. 2 at 4:04 PM
$BFRI $1.20 is big break to upside, 3rd time lucky watch.
0 · Reply
Tonyboner
Tonyboner Jun. 2 at 4:01 PM
$BFRI Im supprised there are only a few watchers playing this one, going up on 2 of the worst biotech days is a good sign not a bad one.
0 · Reply
Tonyboner
Tonyboner Jun. 1 at 7:54 PM
$BFRI Them low 70s are looking good, pretty much a no brain buy with almost break even cash flow, expecting a break out around the $1.20 area into pdufa
0 · Reply
LongBullish
LongBullish May. 30 at 12:37 AM
$BFRI It will be a September to remember 🔥
0 · Reply
EscapePlan
EscapePlan May. 29 at 9:53 PM
$BFRI Just came across this - looks like a hidden gem to me. Net zero cash burn, $10M in Q1 revenue, phase 3 results coming in September, 80% margin - market cap of $11M???! WTF? Surely this should be sitting at 5x or 10x this? At 40m a year with 80% margins we're talking 30m in earnings if you stripped it out? What am i missing?
2 · Reply
tiddyy
tiddyy May. 28 at 5:21 PM
$BFRI I am in again
0 · Reply
BioSpecialOne
BioSpecialOne May. 28 at 3:57 PM
$BFRI The setup on $BFRI requires serious attention, not social media hype. Let's look at the actual business case. This is a recurring revenue model: they bring dermatologists into their ecosystem with the RhodoLED lamp and generate consistent cash flow from Ameluz treatments. The fundamentals are shifting rapidly, posting roughly 80% gross margins and a drastically reduced cash burn that stabilizes their runway. We are tracking a major PDUFA catalyst for sBCC coming in September 2026, alongside label expansions into the acne market. The clinical differentiation is clear and the financial floor is solidifying. Trading the hard data, not the noise.
1 · Reply
BioSpecialOne
BioSpecialOne May. 28 at 2:02 PM
$BFRI Still holding my full position in $BFRI. The clinical data remains rock solid and the setup is incredibly clean. The market might be sleeping on it right now, but a massive breakout is building up under the surface. We trade the data, not the daily noise. The explosion upwards is coming.
0 · Reply
LongBullish
LongBullish May. 27 at 4:15 PM
$CYDY $IBRX $NWBO $BFRI Northwest Biotherapeutics (NWBO) and Biofrontera Inc. (BFRI) share strong bullish potential rooted in their transition from R&D-stage companies to commercial scalability, high-growth target markets, and imminent regulatory catalysts. Both companies position their platforms around targeted, low-toxicity options compared to systemic, destructive treatments like traditional chemotherapy.
2 · Reply
ivo98
ivo98 May. 27 at 6:58 AM
$BFRI Who will have to give in? 🤔🤗
0 · Reply
focafoca99
focafoca99 May. 21 at 1:42 PM
$BFRI joining the Lytham Partners Spring 2026 Investor Conference on May 28, 2026.
0 · Reply